Sinotherapeutics Inc. A (688247.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100005PL9

Price
7.92 CNY
Market cap
3.59 bn CNY
P/E (2025)
75.62
P/S (2025)
8.04
Dividend yield
0.32 %
Net margin
10.63 %
Return on equity (ROE)
3.68 %
Return on assets (ROA)
3.30 %

Sinotherapeutics Inc. A financials

Fiscal year20242025
Revenue511.62 m CNY446.57 m CNY
Gross profit264.15 m CNY176.03 m CNY
Operating income127.81 m CNY61.52 m CNY
EBIT142.08 m CNY53.34 m CNY
Net income127.70 m CNY47.48 m CNY
Diluted EPS – continuing operations0.28 CNY0.10 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Sinotherapeutics Inc. A

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended-release tablets; and mesalamine delayed-release, dapagliflozin and metformin hydrochloride sustained-release, sitagliptin and metformin hydrochloride sustained-release tablets, and ursodeoxycholic ACID Capsules. The company also provides bupropion hydrochloride extended-release tablets, and paroxetine and pregabalin extended-release tablets; propafenone hydrochloride extended-release capsules; and sevelamer carbonate tablets. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.